WHO ICTRP trial
Comparative study of efficacy and safety of Relipoietin and of medicinal drug…
CTRI/2013/01/003325 · Clinical Trials Registry India (CTRI) · Not Recruiting
Key facts
| Trial ID | CTRI/2013/01/003325 |
|---|---|
| Public title | Comparative study of efficacy and safety of Relipoietin and of medicinal drug Eprex® in the treatment of anemia in patients with chronic kidney disease on hemodialysis |
| Scientific title | A prospective, international, multicenter, open-label, randomized, comparative study of efficacy and safety of Relipoietin (Reliance Life Sciences Pvt. Ltd., India) and of medicinal drug Eprex® (Cilag AG, Switzerland) in the treatment of anemia in patients with chronic kidney disease on… |
| Primary sponsor | LOK BETA PHARMACEUTICALS I PVT LTD |
| Registry | Clinical Trials Registry India (CTRI) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Phase 3 |
| Countries | India;Russian Federation |
| Conditions | Health Condition 1: null- Anemic Patients with Chronic Kidney disease on Hemodialysis |
| Interventions | Intervention1: ReliPoietin (Reliance Life Sciences Pvt. Ltd., India): Trade name: ReliPoietin International Nonproprietary Name: Epoetin Alfa Dosage form: solution for intravenous and subcutaneous administration. Composition: Recombinant… |
| Registration date | Jan 23, 2013 |
| Target size | 50 |
| Secondary IDs | RLS-RP-01, Version No.: 1.0, Dated: 07.02.2012 |
| Registry page | ctri.nic.in |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: